Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders
Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit . GAITHERSBURG, Md., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will present body composition data from the Phase 2 MOMENTUM trial of pemvidutide in the treatment of obesity and participate in a panel discussion at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders in Washington, D.C.
在马里兰州盖瑟斯堡，2024年12月02日 (环球新闻社) -- altimmune公司 (纳斯达克: ALT)，一家临床阶段生物制药公司，今天宣布， Scott Harris博士，altimmune公司的首席医疗官，将在华盛顿特区举行的第17届肌少症、消瘦和 wasting 疾病学会国际会议的 Cachexia Regulatory & Trials Update Workshop 上发布 pemvidutide 在肥胖治疗中的第二阶段 MOMENTUm 试验的身体组成数据，并参加一个小组讨论。
Details for the panel discussion are as follows:
小组讨论的详细信息如下:
| Title: | Muscle Wasting in Weight Loss Therapy |
| Session: | Treatment Approaches to Address Muscle Wasting in the Context of Obesity Therapy & Regulatory Issues |
| Presenter: | Scott Harris, M.D., Chief Medical Officer, Altimmune, Inc. |
| Date/Time: | Friday, December 6, 2024 at 9:30 am ET |
| 职称： | 体重减轻疗法中的肌肉消耗 |
| 会议主题： | 在肥胖疗法背景下解决肌肉消耗的治疗方法与监管问题 |
| 报告人： | Scott Harris博士，altimmune公司首席医疗官。 |
| 日期/时间: | 2024年12月6日星期五上午9:30 |
About Altimmune
关于Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit .
altimmune是一家临床阶段生物制药公司，专注于开发创新的下一代基于肽的治疗药物。该公司正在开发pemvidutide，一种GLP-1/胰高血糖素双受体激动剂，用于治疗肥胖和MASH。要了解更多信息，请访问。
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
在领英上关注@Altimmune, Inc.
在Twitter上关注@AltimmuneInc
Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com
公司联系人：
Greg Weaver
首席财务官
电话：240-654-1450
ir@altimmune.com
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
投资者联系人：
Lee Roth
Burns McClellan
电话：646-382-3403
lroth@burnsmc.com
Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com
媒体联系：
Danielle Cantey
Inizio Evoke，生物技术公司
电话：619-826-4657
Danielle.cantey@inizioevoke.com
This press release was published by a CLEAR Verified individual.
此新闻发布是由经过验证的个人发布的。